Circulating antibodies to p40(AIS) in the sera of respiratory tract cancer patients

K. Yamaguchi, M. Patturajan, B. Trink, H. Usadel, W. Koch, J. Jen, D. Sidransky

Research output: Contribution to journalArticlepeer-review

16 Scopus citations


Studies of immune recognition in cancer have defined several tumor antigens using autologous cytotoxic T lymphocytes and by detection of serum antibodies to tumor-associated products such as p53 and HER-2/neu. The AIS gene is a p53 homologue with multiple protein products (p40, p51, p63, p73L) on chromosomal arm 3q, frequently amplified and over-expressed in squamous-cell carcinoma of the respiratory tract. We analyzed the humoral response to p40(AIS) (a core domain of AIS products without the transactivation domain) by Western blot and ELISA using bacterially synthesized p40(AIS) protein. Antibodies were detected in the sera of 17/94 (18%) HNSCCs and 13/76 (17%) lung cancers, including 5/18 (26%) squamous-cell carcinomas. Anti-p40(AIS) antibodies were not associated with factors such as sex, age, histopathological grading, extent or size of primary tumor, lymph node involvement and staging. Our results indicate that amplification and over-expression of p40(AIS) may lead to antigen recognition by an autologous host with cancer. AIS may thus represent a new group of developmentally regulated genes that are recognized as tumor antigens. (C) 2000 Wiley-Liss, Inc.

Original languageEnglish (US)
Pages (from-to)524-528
Number of pages5
JournalInternational Journal of Cancer
Issue number6
StatePublished - Nov 20 2000

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Circulating antibodies to p40(AIS) in the sera of respiratory tract cancer patients'. Together they form a unique fingerprint.

Cite this